The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
Department of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China.
BMJ Open. 2024 Oct 29;14(10):e084130. doi: 10.1136/bmjopen-2024-084130.
Late-life depression (LLD) is a global public health issue, often accompanied by cognitive impairments that can exacerbate the severity of depression and impair social functioning. Despite being a well-established treatment for LLD, the suitability of problem-solving therapy (PST) for individuals with LLD and varying degrees of cognitive impairments warrants further investigation. This paper presents the protocol for a systematic review and meta-analysis of randomised controlled trials (RCTs) aimed at evaluating the effectiveness and acceptability of PST for this specific demographic.
METHODS/ANALYSIS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we will conduct a systematic review to synthesise existing research on PST for individuals in this demographic. We will comprehensively search multiple databases and sources, including PubMed, EMBASE, the Cochrane Database and APA PsycNET from inception to October 2023, without language, publication year or type restrictions. Relevant studies will be manually screened from the references. Only RCTs involving PST for LLD will be included. The primary efficacy outcome will be the standardised mean difference in total scores on continuous depression severity scales across different comparison arms. Data extraction will be conducted independently by two reviewers (CH and J-JW), and methodological rigour will be assessed using the Cochrane Risk of Bias assessment tool. Subgroup and sensitivity analyses will be performed to investigate the impact of concomitant cognitive impairments and to evaluate the robustness of the findings.
The meta-analysis project is expected to be ethically unproblematic and does not require approval from a research ethics committee. The results of this study will be shared through articles in scholarly peer-reviewed journals and presentations in various formats, both print and digital.
CRD42023473782.
老年期抑郁症(LLD)是一个全球性的公共卫生问题,常伴有认知障碍,这可能会加重抑郁的严重程度并损害社会功能。尽管问题解决疗法(PST)是治疗 LLD 的一种成熟方法,但 PST 对不同程度认知障碍的 LLD 患者的适用性仍需要进一步研究。本文介绍了一项系统评价和荟萃分析的方案,旨在评估 PST 对这一特定人群的有效性和可接受性。
方法/分析:我们将遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南,对 PST 治疗这一人群的现有研究进行系统评价。我们将全面搜索多个数据库和来源,包括 PubMed、EMBASE、Cochrane 数据库和 APA PsycNET,从开始到 2023 年 10 月,不限制语言、发表年份或类型。将从参考文献中手动筛选相关研究。只有涉及 PST 治疗 LLD 的 RCT 将被包括在内。主要疗效结果将是不同比较组中连续抑郁严重程度量表总分的标准化均数差。数据提取将由两名评审员(CH 和 J-JW)独立进行,方法学严谨性将使用 Cochrane 偏倚风险评估工具进行评估。将进行亚组和敏感性分析,以研究合并认知障碍的影响,并评估结果的稳健性。
荟萃分析项目预计在伦理上没有问题,不需要研究伦理委员会的批准。这项研究的结果将通过学术同行评议期刊上的文章和各种形式的演示文稿(印刷和数字)进行分享。
PROSPERO 注册号:CRD42023473782。